Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 2607 from our risk checks.
Shanghai Pharmaceuticals Holding Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥11.54 |
52 Week High | CN¥16.60 |
52 Week Low | CN¥10.32 |
Beta | 0.25 |
1 Month Change | -6.94% |
3 Month Change | 0.87% |
1 Year Change | -22.76% |
3 Year Change | -24.38% |
5 Year Change | -33.75% |
Change since IPO | -38.49% |
Recent News & Updates
Recent updates
Shareholder Returns
2607 | HK Healthcare | HK Market | |
---|---|---|---|
7D | -3.5% | -1.8% | 0.3% |
1Y | -22.8% | -29.8% | -12.7% |
Return vs Industry: 2607 exceeded the Hong Kong Healthcare industry which returned -29.8% over the past year.
Return vs Market: 2607 underperformed the Hong Kong Market which returned -12.7% over the past year.
Price Volatility
2607 volatility | |
---|---|
2607 Average Weekly Movement | 4.9% |
Healthcare Industry Average Movement | 6.8% |
Market Average Movement | 7.3% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2607 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2607's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 47,811 | Bo Shen | https://www.sphchina.com |
Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including anti-tumor, heart and cerebral vessels, psychoneural, anti-infection, auto-immunity, digestive tract and metabolism, and respiratory system.
Shanghai Pharmaceuticals Holding Co., Ltd Fundamentals Summary
2607 fundamental statistics | |
---|---|
Market cap | HK$61.99b |
Earnings (TTM) | HK$4.98b |
Revenue (TTM) | HK$275.94b |
13.7x
P/E Ratio0.2x
P/S RatioIs 2607 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2607 income statement (TTM) | |
---|---|
Revenue | CN¥254.88b |
Cost of Revenue | CN¥223.22b |
Gross Profit | CN¥31.66b |
Other Expenses | CN¥27.06b |
Earnings | CN¥4.60b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | 1.24 |
Gross Margin | 12.42% |
Net Profit Margin | 1.80% |
Debt/Equity Ratio | 64.5% |
How did 2607 perform over the long term?
See historical performance and comparison